Lupin receives US FDA approval for Glycerol Phenylbutyrate oral liquid
Global pharma major Lupin announced that it has received approval from the United States Food and Drug Administration for its…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Lupin
Lupin receives ANDA approval for Dapagliflozin, Metformin Hydrochloride extended-release tablets in…
Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug…
Lupin completes acquisition of VISUfarma
The integration of VISUfarma has expanded Lupin’s ophthalmology portfolio to over 60 branded products spanning dry eye, glaucoma,…
Lupin Manufacturing Solutions announces expansion of manufacturing facility at Dabhasa
Lupin Manufacturing Solutions (LMS), a global CRDMO and subsidiary of global pharma major Lupin Limited (Lupin), today announced a…
Lupin and Zydus sign licensing agreement for co-marketing innovative Semaglutide injection in India
Global pharma major Lupin has entered into a Licensing and Supply Agreement with Zydus Lifesciences, an innovation-led…
Redrawing the biopharma map: India’s rise in the biosimilars era
For India’s biopharma sector, 2025 stood out as an inflection point. The approval of 146 recombinant biosimilar therapeutic…
Building India Pharma Inc’s innovation muscle
While we agree that “what got us here (an affordable generics powerhouse) will not get us there (a leader in pharma innovation)”,…
Lupin ranked among top 1% globally in S&P Global Corporate Sustainability Assessment
Company scores 91 out of 100; included in Sustainability Yearbook 2026 for third consecutive year
Lupin receives US FDA approval for Brivaracetam Oral Solution 10 mg/mL
Company initiates US launch following ANDA approval for bioequivalent to Briviact
Lupin receives European Commission approval for biosimilar ranibizumab RanluspecTM
Following positive CHMP opinion, Lupin to commercialise RanluspecTM in EU through Sandoz partnership